ArticleJACC. Case reports2025
ST-Segment Elevation Myocardial Infarction After Pegfilgrastim: Case Report and Review of Mechanistic Considerations.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGranulocyte-colony stimulating factors (G-CSFs) are widely used to prevent chemotherapy-induced neutropenia, but they have been linked to coronary neovascularization and prothrombotic effects. CASE REPORT: A 62-year-old man with small cell lung cancer developed an acute posterior ST-segment elevation myocardial infarction (STEMI) 1 day after receiving 6 mg of pegfilgrastim during his second chemo-immunotherapy cycle. Coronary angiography revealed an occluded right coronary artery without atherosclerosis. Aspiration thrombectomy significantly reduced thrombus burden, restoring TIMI flow grade 3. Initial blood tests showed leukocytosis (white blood cells: 82.13 × 10 DISCUSSION: Marked leukocytosis and thrombocytosis after pegfilgrastim plausibly triggered acute myocardial infarction via leukostasis/hyperviscosity, endothelial activation, neutrophil extracellular traps, and platelet reactivity. To our knowledge, this first reported STEMI after pegfilgrastim warrants vigilance for leukocytosis-related thromboembolic complications in oncology patients. TAKE-HOME-MESSAGES: G-CSF-induced leukocytosis should be considered as a rare cause of acute myocardial infarction in patients without significant cardiovascular history. Thrombectomy remains a valuable adjunctive tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.